These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 26616367

  • 1. The Nitric Oxide Prodrug JS-K Induces Ca(2+)-Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells.
    Liu L, Wang D, Wang J, Wang S.
    J Biochem Mol Toxicol; 2016 Apr; 30(4):192-9. PubMed ID: 26616367
    [Abstract] [Full Text] [Related]

  • 2. JS-K as a nitric oxide donor induces apoptosis via the ROS/Ca2+/caspase-mediated mitochondrial pathway in HepG2 cells.
    Huang Z, Liu L, Chen J, Cao M, Wang J.
    Biomed Pharmacother; 2018 Nov; 107():1385-1392. PubMed ID: 30257354
    [Abstract] [Full Text] [Related]

  • 3. Protein phosphatase 2A activation mechanism contributes to JS-K induced caspase-dependent apoptosis in human hepatocellular carcinoma cells.
    Liu L, Huang Z, Chen J, Wang J, Wang S.
    J Exp Clin Cancer Res; 2018 Jul 09; 37(1):142. PubMed ID: 29986744
    [Abstract] [Full Text] [Related]

  • 4. Protein phosphatase 2A mediates JS-K-induced apoptosis by affecting Bcl-2 family proteins in human hepatocellular carcinoma HepG2 cells.
    Liu L, Huang Z, Chen J, Wang J, Wang S.
    J Cell Biochem; 2018 Aug 09; 119(8):6633-6643. PubMed ID: 29693750
    [Abstract] [Full Text] [Related]

  • 5. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
    Liu Z, Li G, Gou Y, Xiao D, Luo G, Saavedra JE, Liu J, Wang H.
    Biomed Pharmacother; 2017 Aug 09; 92():989-997. PubMed ID: 28605880
    [Abstract] [Full Text] [Related]

  • 6. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.
    Udupi V, Yu M, Malaviya S, Saavedra JE, Shami PJ.
    Leuk Res; 2006 Oct 09; 30(10):1279-83. PubMed ID: 16439016
    [Abstract] [Full Text] [Related]

  • 7. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.
    Dong R, Wang X, Wang H, Liu Z, Liu J, Saavedra JE.
    Biomed Pharmacother; 2017 Apr 09; 88():367-373. PubMed ID: 28122301
    [Abstract] [Full Text] [Related]

  • 8. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.
    Kitagaki J, Yang Y, Saavedra JE, Colburn NH, Keefer LK, Perantoni AO.
    Oncogene; 2009 Jan 29; 28(4):619-24. PubMed ID: 18978812
    [Abstract] [Full Text] [Related]

  • 9. NG, a novel PABA/NO-based oleanolic acid derivative, induces human hepatoma cell apoptosis via a ROS/MAPK-dependent mitochondrial pathway.
    Liu L, Fu J, Li T, Cui R, Ling J, Yu X, Ji H, Zhang Y.
    Eur J Pharmacol; 2012 Sep 15; 691(1-3):61-8. PubMed ID: 22824464
    [Abstract] [Full Text] [Related]

  • 10. A reactive oxygen species activation mechanism contributes to JS-K-induced apoptosis in human bladder cancer cells.
    Qiu M, Chen L, Tan G, Ke L, Zhang S, Chen H, Liu J.
    Sci Rep; 2015 Oct 13; 5():15104. PubMed ID: 26458509
    [Abstract] [Full Text] [Related]

  • 11. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
    Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, Waterhouse DJ, Davies KM, Ji X, Keefer LK.
    Mol Cancer Ther; 2003 Apr 13; 2(4):409-17. PubMed ID: 12700285
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.
    Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM, Tari AM.
    Breast Cancer Res; 2008 Apr 13; 10(3):R44. PubMed ID: 18474097
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.
    Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer LK.
    J Pharmacol Exp Ther; 2011 Feb 13; 336(2):313-20. PubMed ID: 20962031
    [Abstract] [Full Text] [Related]

  • 18. JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin.
    Qiu M, Ke L, Zhang S, Zeng X, Fang Z, Liu J.
    Cancer Chemother Pharmacol; 2017 Aug 13; 80(2):275-286. PubMed ID: 28608259
    [Abstract] [Full Text] [Related]

  • 19. JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.
    Ren Z, Kar S, Wang Z, Wang M, Saavedra JE, Carr BI.
    J Cell Physiol; 2003 Dec 13; 197(3):426-34. PubMed ID: 14566972
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.